The National Institute for Health and Clinical Excellence ([NICE] LONDON, United Kingdom) has published final guidance on the use of Humira® (adalimumab, Abbott Laboratories), a recombinant human monoclonal antibody that binds specifically to TNF-a, for the treatment of psoriatic arthritis (PsA). NICE recommends Humira as a treatment option for adults with active and progressive PsA, defined as peripheral arthritis with three or more tender joints and three or more swollen joints, in addition to PsA that has not responded to at least two standard disease-modifying antirheumatic drugs (DMARDs). NICE is the independent organization responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health in the UK.